BRAF V600-Mutant Solid Tumors With & Without Brain Involvement
Innovation Meets Expertise At Revive
Revive Research Institute is bringing game-changer therapies. Our team of expert physicians is involved in clinical research trials to deliver superior treatment strategies.
Solid tumors are conglomerated masses of cells that may be malignant or benign and they may involve organs like the brain. Solid tumors of the metastatic type that have brain involvement have a poor prognosis with a survival rate usually less than 6 months.
The SOC treatment is local brain therapy however there is an urgent need to identify new treatment approaches that target BRAF V600 mutant cancers both systemically and in the brain.
Revive Research Institute is carrying out a clinical research trial to study a new treatment that may target BRAF V600 mutant tumors.
Join our study and help us in our efforts to advance medicine.
Participation Criteria:
- Be 18 years of age or older.
- Confirmed and documented diagnosis of advanced/metastatic solid tumor including primary brain tumor.
- Comply with study procedures.
- Additional criteria may apply.